FOLH1 and neoplasm: Although 177Lu-DOTATATE, 90Y-DOTATOC, and, increasingly, 177Lu-PSMA (prostate-specific membrane antigen) are widely used throughout Europe, therapy invariably consists of 2 or 4 intravenous administrations of 7.4 GBq, separated by 9–12 wk, mostly regardless of the patient’s size and weight, the extent of positive 111In-octreotide or 68Ga-DOTATATE uptake (measured by SPECT or PET imaging, respectively), or the inherent radiosensitivity of the tumor or patient (8,9).